Pekka Kurki

List of Publications by Year
in descending order

13	569	1162367 8	1125271 13
papers	citations	h-index	g-index

13	13	13	634
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Biosimilars: the science of extrapolation. Blood, 2014, 124, 3191-3196.	0.6	258
2	Interchangeability of Biosimilars: A European Perspective. BioDrugs, 2017, 31, 83-91.	2.2	153
3	Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective. Drugs, 2021, 81, 1881-1896.	4.9	45
4	ECCO position challenged by European drug regulators. Journal of Crohn's and Colitis, 2014, 8, 258.	0.6	40
5	Biosimilar regulation in the EU. Expert Review of Clinical Pharmacology, 2015, 8, 649-659.	1.3	19
6	Regulatory Evaluation of Biosimilars: Refinement of Principles Based on the Scientific Evidence and Clinical Experience. BioDrugs, 2022, 36, 359-371.	2.2	14
7	Compatibility of immunogenicity guidance by the EMA and the US FDA. Bioanalysis, 2019, 11, 1619-1629.	0.6	9
8	Roundtable on biosimilars with European regulators and medical societies, Brussels, Belgium, 12 January 2016. GaBI Journal, 2016, 5, 74-83.	0.4	9
9	Immunogenicity Assessment of Biosimilars. Pharmaceutical Medicine, 2018, 32, 103-121.	1.0	7
10	Medication safety risks to be managed in national implementation of automatic substitution of biological medicines: a qualitative study. BMJ Open, 2019, 9, e032892.	0.8	7
11	Immunogenicity Assessment of Biosimilars: A Multidisciplinary Perspective. AAPS Advances in the Pharmaceutical Sciences Series, 2018, , 489-542.	0.2	4
12	Is There Any Research Evidence Beyond Surveys and Opinion Polls on Automatic Substitution of Biological Medicines? A Systematic Review. BioDrugs, 2021, 35, 547-561.	2.2	3
13	EU Perspective on Biosimilars. AAPS Advances in the Pharmaceutical Sciences Series, 2018, , 145-169.	0.2	1